Sunshine Biopharma Stock Today
| SBFM Stock | USD 2.86 0.13 4.76% |
Performance2 of 100
| Odds Of DistressLess than 24
|
Sunshine Biopharma is selling at 2.86 as of the 30th of November 2024; that is 4.76 percent increase since the beginning of the trading day. The stock's lowest day price was 2.71. Sunshine Biopharma has about a 24 % chance of experiencing some form of financial distress in the next two years of operation and did not have a very good performance during the last 90 trading days. Note, on June 12, 2024, Representative Roger Williams of US Congress acquired under $15k worth of Sunshine Biopharma's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 30th of October 2009 | Category Healthcare | Classification Health Care |
Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada. Sunshine Biopharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. The company has 2 M outstanding shares of which 234.06 K shares are at this time shorted by private and institutional investors with about 1.71 trading days to cover. More on Sunshine Biopharma
Moving against Sunshine Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Sunshine Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Chairman, CEO and Pres | Steve Slilaty | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsSunshine Biopharma can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Sunshine Biopharma's financial leverage. It provides some insight into what part of Sunshine Biopharma's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sunshine Biopharma (SBFM) is traded on NASDAQ Exchange in USA. It is located in 333 Las Olas Way, Fort Lauderdale, FL, United States, 33301 and employs 44 people. Sunshine Biopharma is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 5.46 M. Sunshine Biopharma conducts business under Biotechnology sector and is part of Health Care industry. The entity has 2 M outstanding shares of which 234.06 K shares are at this time shorted by private and institutional investors with about 1.71 trading days to cover.
Sunshine Biopharma currently holds about 41.74 M in cash with (8.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.21.
Check Sunshine Biopharma Probability Of Bankruptcy
Ownership AllocationAbout 97.93 % of Sunshine Biopharma outstanding shares are held by general public with 0.23 (%) owned by insiders and only 1.84 % by institutional holders. On June 12, 2024, Representative Roger Williams of US Congress acquired under $15k worth of Sunshine Biopharma's common stock.
Check Sunshine Ownership Details
Sunshine Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Nordwand Advisors Llc | 2024-09-30 | 500 | |
| Main Street Group Ltd | 2024-06-30 | 3.0 | |
| Rise Advisors, Llc | 2024-09-30 | 1.0 | |
| Jaffetilchin Investment Partners, Llc | 2024-09-30 | 1.0 | |
| Renaissance Technologies Corp | 2024-06-30 | 0.0 | |
| Royal Bank Of Canada | 2024-06-30 | 0.0 | |
| Geode Capital Management, Llc | 2024-06-30 | 0.0 | |
| Bridgeway Capital Management, Llc | 2024-06-30 | 0.0 | |
| Two Sigma Investments Llc | 2024-06-30 | 0.0 | |
| Advisor Group Holdings, Inc. | 2024-06-30 | 0.0 | |
| Xtx Topco Ltd | 2024-06-30 | 0.0 |
Sunshine Biopharma Historical Income Statement
Sunshine Stock Against Markets
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sunshine Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. To learn how to invest in Sunshine Stock, please use our How to Invest in Sunshine Biopharma guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sunshine Biopharma. If investors know Sunshine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sunshine Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (127.90) | Revenue Per Share 197.42 | Quarterly Revenue Growth 0.416 | Return On Assets (0.11) | Return On Equity (0.18) |
The market value of Sunshine Biopharma is measured differently than its book value, which is the value of Sunshine that is recorded on the company's balance sheet. Investors also form their own opinion of Sunshine Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Sunshine Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sunshine Biopharma's market value can be influenced by many factors that don't directly affect Sunshine Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sunshine Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sunshine Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sunshine Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.